In the study mention above, a specific Nek2 kinase inhibitor more efficiently inhibited tumor growth than Hec1/Nek2 inhibitors did [26], suggesting that selective kinase inhibitors of Nek2 might be more beneficial for cancer treatment than Hec1-related inhibitors. Here, NEK2 is linked to neoplasm.